BGNE

BeiGene Ltd

Halal Rating :
Comfortable
Last Price $210.14 Last updated:
Market Cap -
7D Change 13.83%
1 Year Change 34.17%

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange
Next Earnings Date

BeiGene is a global biotechnology company focused on developing innovative and affordable medicines to treat cancer. The company develops, manufactures, and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene has a broad portfolio of oncology drugs and candidates in development, with operations in China, the United States, Europe, and Australia.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $1.0b $1.12b - - 0.00% 0.00%
June 30, 2024 $929.17m $1.02b - $-13225000.0 0.00% 1.29%
March 31, 2024 $751.65m $996.84m - $-16160000.0 0.00% 1.62%

Company Impact

Help us evaluate BeiGene Ltd's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Recent News & Updates